CoChat

Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes

Open access
Hightower, Kendra E., Wang, Ruolan, DeAnda, Felix, Johns, Brian A., Weaver, Kurt, Shen, Yingnian, Tomberlin, Ginger H., Carter, H. Luke, Broderick, Timothy, Sigethy, Scott, Seki, Takahiro, Kobayashi, Masanori, Underwood, Mark R. · 2011 · Antimicrobial Agents and Chemotherapy

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

The integrase inhibitor (INI) dolutegravir (DTG; S/GSK1349572) has significant activity against HIV-1 isolates with raltegravir (RAL)- and elvitegravir (ELV)-associated resistance mutations. As an initial step in characterizing the different resistance profiles of DTG, RAL, and ELV, we determined the dissociation rates of these INIs with integrase (IN)-DNA complexes containing a broad panel of IN proteins, including IN substitutions corresponding to signature RAL and ELV resistance mutations. DTG dissociates slowly from a wild-type IN-DNA complex at 37°C with an off-rate of 2.7 × 10 −6 s −1 and a dissociative half-life ( t 1/2 ) of 71 h, significantly longer than the half-lives for RAL (8.8 h) and ELV (2.7 h). Prolonged binding ( t 1/2 , at least 5 h) was observed for DTG with IN-DNA complexes containing E92, Y143, Q148, and N155 substitutions. The addition of a second substitution to either Q148 or N155 typically resulted in an increase in the off-rate compared to that with the single substitution. For all of the IN substitutions tested, the off-rate of DTG from IN-DNA complexes was significantly slower (from 5 to 40 times slower) than the off-rate of RAL or ELV. These data are consistent with the potential for DTG to have a higher genetic barrier to resistance, provide evidence that the INI off-rate may be an important component of the mechanism of INI resistance, and suggest that the slow dissociation of DTG may contribute to its distinctive resistance profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/aac.00157-11

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Research works printed but not linked: 9

  1. DeAndaF. HattoriK. YoshinagaT. KawasujiT. UnderwoodM. R.. 2010. Structural models of HIV-1 integrase and DNA in complex with S/GSK1349572, raltegravir, or elvitegravir: structure-based rationale for INI resistance profiles. Antiviral Ther. 15(Suppl. 2):A73.
  2. DeAndaF. . 2010. Structural rationale for slow S/GSK1349572 dissociation from wild type (WT) and raltegravir (RAL) resistant HIV-1 integrase (IN), abstr. H-1166. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
  3. DeJesusE. . 2007. First report of raltegravir (RAL, MK-0518) use after virologic rebound on elvitegravir (EVT, GS 9137), abstr. TUPEB032. Abstr. 4th Int. AIDS Soc. Conf. HIV Pathogenesis, Treatment, Prevention. International AIDS Society, Geneva, Switzerland.
  4. DickerI. B. . 2011. Longer integrase inhibitor dissociation half-lives induce persistent anti-HIV effects in cell culture, abstr. 521. Abstr. 18th Conf. Retrovir. Opportunistic Infect.
  5. GroblerJ. A. . 2009. Functionally irreversible inhibition of integration by slowly dissociating strand transfer inhibitors, abstr. O-10. Abstr. 10th Int. Workshop Clin. Pharmacol. HIV Ther.
  6. HluhanichR. . 2010. HIV integrase inhibitors (INIs) do not exert a post-antibiotic effect (PAE) despite slow dissociation from IN-DNA complexes in vitro, abstr. H-930. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
  7. JohnsB. . 2010. The discovery of S/GSK1349572: a once-daily next generation integrase inhibitor with a superior resistance profile, abstr. 55. Abstr. 17th Conf. Retrovir. Opportunistic Infect.
  8. UnderwoodM. R. JohnsB. SatoA. FujiwaraT. SpreenW.. 2009. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy, abstr. WEPEA098. Abstr. 5th Int. AIDS Soc. Conf. HIV Pathogenesis, Treatment, Prevention. International AIDS Society, Geneva, Switzerland.
  9. YoshinagaT. Kanamori-KoyamaM. SekiT. SatoA. FujiwaraT.. 2010. Strong inhibition of wild-type and integrase inhibitor (INI)-resistant HIV integrase (IN) strand transfer reaction by the novel INI S/GSK1349572. Antivir. Ther. 15(Suppl. 2):A12.

Cited by

See all 258

Metadata

Authors
Hightower, K. E., Wang, R., DeAnda, F., Johns, B. A., Weaver, K., Shen, Y., Tomberlin, G. H., Carter, H. L., Broderick, T., Sigethy, S., Seki, T., Kobayashi, M., & Underwood, M. R.
Affiliations
  • GlaxoSmithKline, Research Triangle Park, North Carolina
  • Shionogi (Japan) (JP)
Corresponding author
Underwood, Mark R.
Venue
Antimicrobial Agents and Chemotherapy
Published
2011-10
Volume
55
Issue
10
Pages
4552-4559
ISSN
  • 0066-4804 (ISSN-L)
  • 1098-6596
OpenAlex
W2144255757
Cited by
226
References
39
Citations by year
2026: 3 · 2025: 10 · 2024: 8 · 2023: 10 · 2022: 10 · 2021: 13 · 2020: 9 · 2019: 16 · 2018: 11 · 2017: 19 · 2016: 16 · 2015: 32 · 2014: 27 · 2013: 23 · 2012: 17
FWCI
14.89
Type
journal article
Language
en
Open access
Licence
journals.asm.org/non-commercial-tdm-license (tdm)
Locations
  • Antimicrobial Agents and Chemotherapy (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
Keywords
dolutegravir, raltegravir, elvitegravir, HIV-1 integrase inhibitors, integrase inhibitor resistance, integrase-DNA complex, dissociation rate, dissociation rate constant, resistance mutations, resistance mechanisms
MeSH terms
Raltegravir Potassium, Dolutegravir, DNA, Viral, Genotype, Heterocyclic Compounds, 3-Ring, Mutation, Oxazines, Piperazines, Pyridones, Pyrrolidinones, Quinolones, HIV-1, DNA, Complementary, HIV Integrase, HIV Integrase Inhibitors, Amino Acid Substitution, Drug Resistance, Viral

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes. https://app.cochat.ai/papers/10.1128/aac.00157-11
The paper
Hightower, K. E., Wang, R., DeAnda, F., Johns, B. A., Weaver, K., Shen, Y., Tomberlin, G. H., Carter, H. L., Broderick, T., Sigethy, S., Seki, T., Kobayashi, M., & Underwood, M. R. (2011). Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00157-11

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.